Healthcare Industry News: XP13512
News Release - July 15, 2008
XenoPort Appoints David A. Stamler, M.D., as Chief Medical OfficerSANTA CLARA, Calif.--(HSMN NewsFeed)--XenoPort, Inc. (Nasdaq:XNPT ) announced today that David A. Stamler, M.D., has joined the company as senior vice president and chief medical officer. Dr. Stamler brings to XenoPort over 15 years of clinical development experience, most recently as the chief scientific officer and head of drug development for Prestwick Pharmaceuticals, Inc.
“We are excited to have David join the XenoPort executive team,” said Ronald W. Barrett, Ph.D., chief executive officer of XenoPort. “David’s broad experience and expertise in CNS drug development at small and large biopharmaceutical companies will be of tremendous value as we advance our pipeline of product candidates. We also look forward to David’s contributions to our joint efforts to develop Solzira™/XP13512 with GlaxoSmithKline and Astellas.”
Prior to Prestwick, Dr. Stamler was employed by Fujisawa Pharmaceutical Company, where he was most recently the senior global project leader for CNS Diseases and vice president of research and development, Medical Sciences for Fujisawa’s U.S. subsidiary. Prior to Fujisawa, Dr. Stamler was employed by Abbott Laboratories, where he was director of clinical research, Pharmaceutical Products for the International Division.
Dr. Stamler received his B.A. and M.D. degrees from the University of Chicago. He completed his residency in internal medicine at Temple University Hospital, as well as fellowships in infectious diseases and clinical microbiology at the University of Pennsylvania. He is board certified in internal medicine. Dr. Stamler is a founding member of the American Society of Experimental NeuroTherapeutics (ASENT) and a member of the American Academy of Neurology and the American College of Physicians. He has authored publications in peer-reviewed scientific journals for CNS, gastrointestinal, respiratory and inflammatory diseases.
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. Its development and commercialization efforts are currently focused on potential treatments of central nervous system disorders. XenoPort’s most advanced product candidate, XP13512, which is known as Solzira in the U.S., has successfully completed three pivotal trials in its Phase 3 clinical program for the treatment of moderate-to-severe primary restless legs syndrome, or RLS. It has also successfully completed a Phase 2a clinical trial for the management of post-herpetic neuralgia and is currently being evaluated by XenoPort’s partners, Astellas Pharma Inc. and GlaxoSmithKline, in Phase 2 clinical trials as a potential treatment for neuropathic pain and by Astellas in a Phase 2 clinical trial as a potential treatment for RLS. XenoPort has reported positive results from a Phase 2a clinical trial of its second product candidate, XP19986, in patients with gastroesophageal reflux disease, or GERD, and is currently conducting a second Phase 2 clinical trial in GERD patients. It is also evaluating XP19986 as a potential treatment of patients with spasticity related to spinal cord injury. XenoPort’s third product candidate, XP21279, has been evaluated in a Phase 1 clinical trial that showed positive data for its use as a potential treatment for Parkinson’s disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
This press release contains “forward-looking” statements, including, without limitation, all statements related to XenoPort’s and its partners’ future clinical development of XP13512 (Solzira) and the timing thereof; XenoPort’s future clinical development programs and the timing thereof; the therapeutic and commercial potential of XP13512, XP19986 and XP21279; the suitability of XP19986 as a treatment for GERD and spasticity; and the suitability of XP21279 as a treatment for Parkinson’s disease. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “could,” “plans,” “expects,” “will,” “intends,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort's current expectations. Forward-looking statements involve risks and uncertainties. XenoPort's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the uncertain results of clinical trials; XenoPort’s or its partners’ ability to successfully conduct clinical trials for XP13512, XP19986 and XP21279 in the anticipated timeframes, or at all; the uncertainty of the FDA approval process and other regulatory requirements; XenoPort’s dependence on its current and additional collaborative partners; and the uncertain therapeutic and commercial value of its compounds. These and other risk factors are discussed under the heading “Risk Factors” in XenoPort’s Annual Report on Form 10-Q for the quarter ended March 31, 2008, filed with the Securities and Exchange Commission on May 8, 2008. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
XenoPort is a registered U.S. trademark.
Solzira is a U.S. trademark of GSK.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.